Brown Adipose Secretome Biomarkers in Metabolic Regulation

Abstract

Brown adipose tissue (BAT) is an evolutionarily conserved thermogenic organ that has gained considerable attention for its role in systemic metabolic regulation. The secretome of BAT encompasses a diverse array of batokines proteins, peptides, lipids, and metabolites implicated in inter-organ communication and energy homeostasis. Recent studies have highlighted the potential of BAT-derived secretome biomarkers to serve as novel indicators and modulators of metabolic health, offering promising avenues for the assessment and management of obesity, type 2 diabetes mellitus (T2DM), and cardiometabolic disease. This review synthesizes current evidence regarding the epidemiology, pathophysiological mechanisms, clinical implications, diagnostic strategies, therapeutic avenues, and guideline-based recommendations for integrating BAT secretome biomarkers into metabolic disease management.

Introduction

Brown adipose tissue, distinct from white adipose tissue (WAT), is characterized by its multilocular lipid droplets, dense mitochondrial content, and expression of uncoupling protein 1 (UCP1). BAT activation is associated with increased energy expenditure and improved glucose and lipid metabolism. In recent years, the BAT secretome has emerged as a critical mediator of its systemic effects. BAT-secreted factors such as fibroblast growth factor 21 (FGF21), neuregulin 4 (NRG4), and various microRNAs have been implicated in metabolic cross-talk, positioning BAT as an endocrine organ with significant clinical relevance. Understanding the landscape of BAT secretome biomarkers is essential for enhancing the precision of metabolic disease diagnosis and therapy.

Epidemiology / Disease Burden

The global rise in obesity and T2DM underscores the urgent need for novel diagnostic and therapeutic strategies. Epidemiological studies reveal that BAT prevalence and activity decrease with age, body mass index (BMI), and insulin resistance. Notably, individuals with metabolically healthy phenotypes tend to exhibit higher BAT activity and favorable secretome profiles. The loss of BAT function and altered batokine secretion patterns are correlated with increased cardiometabolic risk, indicating that BAT secretome biomarkers may serve as early indicators of metabolic derangement and disease burden.

Pathophysiology

The pathophysiological basis of BAT’s influence on metabolism lies in its thermogenic and secretory properties. Upon cold stimulation or β-adrenergic activation, BAT secretes a spectrum of factors into circulation. FGF21 enhances glucose uptake and insulin sensitivity; NRG4 suppresses hepatic lipogenesis; and the secreted enzyme CXCL14 modulates immune cell recruitment. Additionally, BAT-derived exosomal microRNAs can alter gene expression in distant tissues. Dysregulation of these secretome components contributes to impaired energy expenditure, ectopic fat deposition, and insulin resistance, perpetuating the pathogenesis of obesity and T2DM.

Risk Factors

Key risk factors for BAT dysfunction and altered secretome profiles include advanced age, sedentary lifestyle, chronic overnutrition, environmental temperature (reduced cold exposure), and certain genetic polymorphisms affecting BAT differentiation and function. Endocrine disorders (e.g., hypothyroidism, Cushing’s syndrome) and medications such as β-blockers can also impair BAT activity and secretome output, predisposing individuals to adverse metabolic outcomes.

Clinical Features

While BAT dysfunction does not produce overt symptoms, indirect clinical manifestations include progressive weight gain, central adiposity, impaired glucose tolerance, and dyslipidemia. In metabolic syndrome patients, reduced circulating levels of beneficial batokines (e.g., FGF21, NRG4) often coincide with increased inflammatory and atherogenic biomarkers, suggesting a shift in the BAT secretome toward a pro-metabolic disease profile.

Diagnosis

Assessment of BAT secretome biomarkers in clinical practice remains primarily research-based but is rapidly advancing. Non-invasive imaging modalities such as ^18F-FDG PET/CT can localize and quantify BAT mass and activity. Circulating levels of key batokines (e.g., FGF21, NRG4, IL-6) can be measured using enzyme-linked immunosorbent assays (ELISA) or multiplex proteomics. The identification of novel batokine panels may enable earlier detection of metabolic risk and personalized patient stratification.

Treatment & Management

Therapeutic strategies aimed at enhancing BAT activity and optimizing its secretome include lifestyle interventions (cold exposure, structured exercise), pharmacotherapy (β3-adrenergic agonists, GLP-1 receptor agonists), and nutritional modulation (polyphenols, ω-3 fatty acids). Early-phase clinical trials are investigating recombinant batokines and exosome-based therapies for metabolic disease modification. Integrating BAT secretome biomarker monitoring may refine treatment efficacy assessment and guide individualized care plans.

Recent Advances / Emerging Therapies

Recent advances include the discovery of additional batokines such as meteorin-like and lipokines (e.g., 12,13-diHOME), which exert anti-inflammatory and insulin-sensitizing effects. Novel imaging tracers and high-throughput proteomics are expanding the repertoire of measurable BAT secretome components. Gene editing approaches targeting BAT differentiation and function, as well as stem cell therapies, represent exciting future directions. The potential for BAT secretome modulation to prevent or reverse metabolic disease is being actively explored in translational studies.

Guideline Recommendations

While formal clinical guidelines incorporating BAT secretome biomarkers are not yet established, expert consensus highlights the importance of BAT assessment in metabolic health evaluation. The Endocrine Society and ADA recommend considering BAT activity in obesity and T2DM management research. Ongoing guideline development is anticipated as evidence matures, particularly emphasizing biomarker-driven risk stratification and targeted intervention.

Conclusion

BAT secretome biomarkers represent a transformative frontier in metabolic medicine, offering novel insights into disease mechanisms and intervention opportunities. Advances in biomarker discovery, validation, and clinical translation promise to enhance early detection, individualized therapy, and long-term outcomes for patients with obesity and T2DM. Continued multidisciplinary research and integration of BAT secretome assessment into clinical workflows will be pivotal in realizing the full potential of this emerging paradigm in metabolic regulation.